Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03748875
Recruitment Status : Not yet recruiting
First Posted : November 21, 2018
Last Update Posted : January 10, 2020
Sponsor:
Information provided by (Responsible Party):
Shanghai Mental Health Center

Brief Summary:
Amphetamine-type stimulants (ATSs) have become the most important medical issue as well as the social problem. Compared with traditional drugs, ATS are highly neurotoxin and can induce cognitive deficit and psychotic symptoms. Due to lack of efficient medical treatment, psychotherapy and behavioral interventions are the main treatment strategies so far. Mindful-based relapse prevention (MBRP) which combined mindfulness with relapse prevention skills, as a novel intervention, has been widely used in prevent craving and relapse among addictions. While the current research of MBRP mechanism focus on emotion regulation circuit, and there was no study to explore the impulsive circuit, which is the important factor that induce the addiction and relapse. However, there was no report about the influence of MBRP on Prefrontal-striatal circuits. Based on the previous results, the proposed study will focus on evaluating the mechanism of MBRP on prefrontal-striatal circuits, neuropsychological tests and functional MRI will be used to investigate the neurobiological mechanism of MBRP on prefrontal-striatal circuits and related impulsive behaviors.

Condition or disease Intervention/treatment Phase
Methamphetamine-dependence Behavioral: mindfulness-based relapse prevention Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents
Estimated Study Start Date : May 1, 2020
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine

Arm Intervention/treatment
Experimental: Intervention group
an 8-session mindfulness-based relapse prevention program
Behavioral: mindfulness-based relapse prevention
mindfulness-based relapse prevention, 8 weeks

No Intervention: Control group
treatment as usual



Primary Outcome Measures :
  1. craving change [ Time Frame: change from baseline, 4,8,12,27and 52 weeks ]
    craving will be measured by visual analogue scale(VAS), participants specify their level of craving by indicating a position along a continuous line between two end-points, score ranges from 0 to 10, 0 refers to the lowest level of craving, 10 refers to the highest level of craving

  2. impulsiveness change [ Time Frame: baseline,4,8,12,27and 52 weeks ]
    impulsiveness will be measured by Barratt Impulsiveness Scale, the scale is a 30 item self-report measure, Rarely/Never = 1,Occasionally = 2,Often = 3,Almost Always/Always = 4. Assessment is indicated by the total score added together.

  3. functional connectivity change between prefrontal cortex and striatum [ Time Frame: baseline, 8 and 12weeks ]
    functional connectivity between prefrontal cortex and striatum will be measured by fMRI


Secondary Outcome Measures :
  1. cognitive function improvement [ Time Frame: baseline,4,8,12,27and 52 weeks ]
    cognitive function improvement will be measured by Cogstate system

  2. depression level change [ Time Frame: baseline,4,8,12,27and 52 weeks ]
    depression level will be measured by patient health questionnaire-9(PHQ-9). The Patient Health Questionnaire (PHQ) is a multiple-choice self-report inventory, and The PHQ-9 is a tool specific to depression which has 9 items. Assessment is indicated by the total score, which made up by adding together the scores for the scale all seven items.System of scoring is Not at all (0 points),Several days (1 point) More than half the days (2 points) and Nearly every day (3 points).PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

  3. anxiety level change [ Time Frame: baseline,4,8,12,27and 52 weeks ]
    anxiety level will be measured by Generalized Anxiety Disorder(GAD-7). it has 7 items and measure severity of various signs of GAD according to reported response categories with assigned points. Assessment is indicated by the total score, which made up by adding together the scores for the scale all seven items.System of scoring is Not at all (0 points),Several days (1 point) More than half the days (2 points) and Nearly every day (3 points).

  4. addiction severity change [ Time Frame: baseline,4,8,12,27and 52 weeks ]
    addiction severity will be measured by addiction severity index(ASI). ASI is a semi-structured instrument used in face-to-face interviews conducted by clinicians, researchers or trained techniciansIt measures Medical issues relating to drug use, Employment/Support Status, Levels of Alcohol and Drug Use, Legal Issues Arising from Substance Abuse, Family/Social Factors and Psychiatric/Mental Health Status. Severity ratings are based on the following 10 point scale (0-9).0-1: No real problem, treatment not indicated, 2-3: Slight problem, treatment probably not necessary 4-5: Moderate problem, some treatment indicated 6-7: Considerable problem, treatment necessary 8-9: Extreme problem, treatment absolutely necessary



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-45 years old, male or female, with 9 years of education or above, can cooperate with the completion of the questionnaire evaluation;
  • Comply with DSM-V diagnostic criteria for amphetamine-based addiction;
  • The previous use of amphetamines for not less than 1 year (at least once a week);
  • Vision and hearing are normal, or in the normal range after correction. No contraindications for magnetic resonance imaging;
  • agree to cooperate with the completion of follow-up evaluation;
  • The Mindfulness Attention Awareness Scale score is greater than 50 points.

Exclusion Criteria:

  • Severe cognitive dysfunction, such as history of head trauma, cerebrovascular disease, epilepsy, etc., drugs used to promote cognitive function in the last 6 months; intellectual impairment IQ<70;
  • There have been other abuse or dependence of psychoactive substances in the past 5 years (excluding nicotine); 100 healthy controls have been publicly collected by the public. Exclude serious physical illness and mental damage. through
  • SCID clinical interviews exclude family history of mental disorders and psychosis, no history of substance abuse (except nicotine).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748875


Contacts
Layout table for location contacts
Contact: Jiang DU, Doctor 021-64906315 dujiangdou@163.com

Sponsors and Collaborators
Shanghai Mental Health Center
Layout table for additonal information
Responsible Party: Shanghai Mental Health Center
ClinicalTrials.gov Identifier: NCT03748875    
Other Study ID Numbers: JDu-006
First Posted: November 21, 2018    Key Record Dates
Last Update Posted: January 10, 2020
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Shanghai Mental Health Center:
Mindfulness-based relapse prevention
methamphetamine
Prefrontal-striatal circuit
impulsive
mechanism
Additional relevant MeSH terms:
Layout table for MeSH terms
Recurrence
Impulsive Behavior
Disease Attributes
Pathologic Processes